Argen-X Launches NHance(TM) Technology to Generate Better Human Antibody Therapies
ROTTERDAM, the Netherlands and GHENT, Belgium, March 19, 2012 /PRNewswire/ –
ADDS A SECOND PROPRIETARY TECHNOLOGY TO LEVERAGE THE POWER OF THE SIMPLE ANTIBODY(TM)
arGEN-X announces today the launch of NHance(TM), its latest cutting-edge technology
enabling the creation of truly differentiated human antibody therapeutics.
NHance(TM) technology significantly prolongs the circulation time of therapeutic
antibodies in the human body by engineering of the antibody constant region (Fc). The
technology provides a new treatment paradigm in terms of reduced antibody dosing,
increased efficacy and improved overall convenience to the patient.
Nhance(TM) is superior to existing Fc engineering approaches delivering superior
pharmacokinetics without impairing the antibody’s Fc-mediated cell-killing effects. The
technology has been thoroughly validated, including through PK studies in appropriate
NHance(TM) is based on proprietary Fc region mutations and was invented by Dr. Sally
Ward, Professor of Immunology at the University of Texas Southwestern Medical Center, a
world renowned pioneer in this field of antibody biology. arGEN-X has acquired an
exclusive global license to the technology.
arGEN-X will apply the NHance(TM) technology both to its partners’ antibody discovery
programs and to its own therapeutic antibody pipeline. In addition, arGEN-X intends to
make the technology available to antibody-focused companies through non-exclusive
“Our validated SIMPLE Antibody(TM) platform, which delivers variable regions
unrivalled in their functional diversity and therapeutic utility, is key to arGEN-X’s
success,” says Prof. Dr. Hans de Haard, Chief Scientific Officer. “We had previously
complemented the SIMPLE platform with state-of-the-art ADCC-enhancement through our
Potelligent(R) license agreement with BioWa. We are now further strengthening our
cutting-edge capabilities with NHance(TM) to ensure the optimal differentiation of our
antibody products. This suite of technologies underpins our evolution into a real
therapeutic antibody powerhouse.”
Dr. Torsten Dreier, Chief Development Officer of arGEN-X, comments further: “I am
thrilled by the therapeutic potential of NHance(TM), which delivers increased efficacy in
settings where sustained antibody dosing is critically important. NHance(TM) is a great
solution for improving the dosing convenience for chronically ill patients as well as
maximizing the cost-effectiveness of therapeutic antibody treatments.”
About arGEN-X – http://www.arGEN-X.com
arGEN-X is a preclinical stage biopharmaceutical company that is rapidly leveraging
the power of its broadly applicable, proprietary SIMPLE Antibody(TM) platform to generate
fully human antibodies with differentiated qualities and outstanding therapeutic
potential. The platform excels in delivering large panels of ultra-potent, functionally
diverse antibodies against complex disease targets, especially cell surface receptors and
highly conserved proteins. The superior choice that arGEN-X brings to antibody discovery
enables it to prioritise leads with best-in-class therapeutic properties, thereby
increasing the probability of development success. Antibody leads generated from the
SIMPLE Antibody(TM) platform have outstanding physicochemical properties and consistent
manufacturability, enabling a seamless transition from discovery into development. arGEN-X
has validated its technology on multiple diverse classes of targets to date and has
successfully delivered in its collaboration with Eli Lilly & Co. Recently, arGEN-X entered
into a second strategic alliance with the specialty biopharmaceutical company Shire which
is focused on the discovery and development of therapeutics for rare diseases.
In addition, arGEN-X is applying the NHance(TM) and Potelligent(R) technologies to
further maximize the therapeutic utility of its SIMPLE Antibodies.
NHance(TM)is an arGEN-X proprietary technology capable of enhancing the half life of a
therapeutic antibody in the human systemic circulation. NHance(TM) achieves this through 2
specific mutations in the antibody Fc region (at His433 and Asn434), resulting in an
improved affinity at acidic pH for the antibody for binding to the neonatal Fc receptor.
This receptor is responsible for recycling the antibody within the human body. Enhanced
antibody serum levels may result in a higher therapeutic effect of this antibody, lower
material requirements of the antibody for the same therapeutic effect, and/or reduced
dosing frequency of the antibody. The technology may further enhance the transport across
the mucosal barrier, enabling alternative routes of antibody administration.
The SIMPLE Antibody(TM) and NHance(TM) platforms are covered by broad patent claims,
enjoying an independent, unencumbered patent position and are free of target gatekeeping
SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.
arGEN-X(TM), SIMPLE Antibody(TM) and NHance(TM) are deposited trademarks of arGEN-X
Potelligent(R) is a deposited trademark of Biowa Inc.
For licensing inquiries about NHance(TM), please contact Business.Development@arGEN-X.com For further information, please contact: Citigate Dewe Rogerson David Dible Mark Swallow Nina Enegren T: +44(0)207-282-2949/2948/1050 E: firstname.lastname@example.org arGEN-X Tim Van Hauwermeiren, MSc, eMBA Chief Executive Officer T: +31-6-122-85-257 E: tim.vh@arGEN-X.com Debbie Allen, Ph.D. Senior Director, Business Development T: +44(0)7974-979479 E: dallen@arGEN-X.com